Servier Continues Oncology Winning Streak With Tibsovo Approval For MDS

 
• By Alaric DeArment
  
The FDA approved Servier's Tibsovo for IDH1-mutated relapsed/refractory myelodysplastic syndrome • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip